## MCK: McKesson Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($794.88)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. McKesson Builds Earnings Momentum on Specialty and Automation**
- Source: TradingView — Track All Markets | 20260105T190833 | Bullish | Relevance: 100%
- McKesson delivered a strong fiscal second quarter with consolidated revenues of $103 billion, up 10% year-over-year, and adjusted earnings per diluted share rising 39% to $9.86, leading management to raise full-year guidance. The company’s growth is driven by its North American Pharmaceutical distribution, accelerating specialty volumes, and rising contributions from prescription technology services, particularly within oncology and multispecialty segments. McKesson's long-term strategy focuses on scaling differentiated specialty platforms, leveraging technology and automation for efficiency, and expanding its presence in the biopharma and provider ecosystem.

**2. McKesson Corporation: How a 192-Year-Old Giant Is Rebuilding the Digital Railroads of Healthcare**
- Source: AD HOC NEWS | 20260103T162057 | Bullish | Relevance: 100%
- McKesson Corporation, a 192-year-old giant, is transforming from a drug distributor into a data-driven healthcare infrastructure platform. The company is leveraging its extensive distribution network, technology, and services to orchestrate inventory, reimbursement, clinical workflows, and real-world data, especially for complex therapies. This strategic shift is reflected in its stock performance, with investors increasingly valuing the higher-margin specialty services and technology solutions over traditional distribution activities.

**3. McKesson Corporation: How a 192-Year-Old Giant Is Rebuilding the Digital Railroads of Healthcare**
- Source: AD HOC NEWS | 20260103T160810 | Bullish | Relevance: 100%
- McKesson Corporation is transforming from a traditional drug distributor into a data-driven healthcare infrastructure platform leveraging technology, services, and scale to reshape healthcare economics. The company excels in orchestrating complex logistics for specialty drugs, embedding itself into clinical and pharmacy workflows, and utilizing data for insights, positioning it as an indispensable operating platform for modern healthcare delivery. This strategic shift towards higher-margin services and technology-enabled offerings is directly impacting its stock valuation, reflecting a multi-year rerating by the market.

**4. McKesson Corporation: How a Quiet Infrastructure Giant Is Rewiring Healthcare Distribution**
- Source: AD HOC NEWS | 20260105T162734 | Bullish | Relevance: 100%
- McKesson Corporation is transforming from a traditional drug wholesaler into a data-driven healthcare infrastructure platform, leveraging technology, scale, and an extensive ecosystem. This strategic shift involves moving beyond mere distribution to providing critical infrastructure for modern healthcare, highlighted by its focus on specialty and oncology services, alongside comprehensive technology and data solutions. The company's unique approach, combining massive scale with specialization and ecosystem neutrality, positions it as an indispensable partner across the healthcare value chain, driving investor enthusiasm for McKesson Aktie.

**5. Motco Buys 14,613 Shares of McKesson Corporation $MCK**
- Source: MarketBeat | 20260105T130931 | Bullish | Relevance: 100%
- Motco significantly increased its stake in McKesson Corporation, purchasing 14,613 additional shares and now owning a total of 14,642 shares valued at $11.31 million. McKesson exceeded EPS expectations in its latest quarter, and analysts largely rate the stock as a "Moderate Buy" with an average price target of $892.86. The company also recently announced a quarterly dividend, and various other institutional investors have modified their holdings.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $960 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.3%)
- Blackrock Inc.: 9.2% (+0.4%)
- State Street Corpora: 4.7% (+0.9%)
- JPMORGAN CHASE & CO: 4.5% (+16.0%)
- Massachusetts Financ: 3.2% (-1.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.99 indicates undervaluation relative to growth. Balance sheet: $2.3B free cash flow. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $102.6B |
| Beta | 0.41 |
| 52W Range | $570.51 - $895.58 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.99 |
| Forward P/E | 18.8 |
| Current P/E | 21.3 |
| YoY Growth | 13.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at 0.1% (minimal 5-day change). Below STRENGTH zone by 2.9pp (needs >3.0% for momentum thesis). MRS_5 (-0.3%) diverging from MRS_10 - short-term weakness emerging. MACD histogram positive (0.94), confirming momentum. RSI neutral at 50. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.13% (CS: 42) | Neutral |
| RSI_14 | 50.4 | Neutral |
| MACD Histogram | 0.94 | Bullish |
| vs SMA20 | 1.009x | Above |
| vs SMA50 | 0.992x | Below |
| vs SMA200 | 1.114x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $824.48
- **Stop Loss:** $794.88 (3.6% risk)
- **Target:** $854.08 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 29
- **Position Value:** $23,909.92
- **Portfolio %:** 23.91%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-04 (Est: $9.28)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.05 | $9.86 | +8.9% |
| 2025Q2 | $8.15 | $8.26 | +1.4% |
| 2025Q1 | $9.83 | $10.12 | +3.0% |
| 2024Q4 | $7.99 | $8.03 | +0.5% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_10*